Director Corey Michael Watton filed a Form 4 with the SEC on August 12, 2026, disclosing the exercise of stock options and the same-day sale of shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) on August 10, 2026.

Key Highlights

  • Option exercise: Watton exercised a stock option for 12,300 shares of common stock at an exercise price of $4.97 per share on August 10, 2026.
  • Same-day sale: Watton disposed of 12,300 shares of common stock at a weighted average price of $11.2502 per share, with individual trade prices ranging from $11.23 to $11.31.
  • Remaining common stock: Following the transactions, Watton directly holds 1,800 shares of common stock.
  • Remaining options: Watton retains 46,500 stock options with an exercise price of $4.97 and an expiration date of May 2, 2033.
  • Option grant date: The exercised option was granted on May 3, 2023, and was fully vested at the time of exercise.

Watton's Option Exercise and Share Sale at Zevra Therapeutics

According to the filing, Corey Michael Watton, a director of Zevra Therapeutics, Inc., reported two transactions dated August 10, 2026. In the first transaction, coded "M," Watton acquired 12,300 shares of common stock through the exercise of a stock option at the conversion price of $4.97 per share, bringing his direct beneficial ownership of common stock to 14,100 shares at that point.

In the second transaction, coded "S," Watton disposed of 12,300 shares of common stock. The filing states the transaction was executed in multiple trades at prices ranging from $11.23 to $11.31, with the reported price of $11.2502 reflecting the weighted average sale price. The filing notes that Watton "undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected." After this sale, Watton's direct beneficial ownership of common stock stood at 1,800 shares.

With respect to derivative securities, the filing discloses that the exercised option, originally granted on May 3, 2023, carried an exercise price of $4.97 and an expiration date of May 2, 2033. The filing states the shares underlying this option "were fully vested." Following the exercise of 12,300 options, Watton directly holds 46,500 remaining stock options. The Form 4 was signed by Timothy J. Sangiovanni as attorney-in-fact for Corey M. Watton and was filed on August 12, 2026.

What Was Disclosed

The filing disclosed a same-day option exercise and share sale by Zevra Therapeutics director Corey Michael Watton on August 10, 2026, involving 12,300 shares of common stock, with a weighted average sale price of $11.2502 and 1,800 shares and 46,500 options remaining after the transactions.